Loading stock data…
Janux Therapeutics, Inc. (JANX)
$20.04-0.20 (-0.99%)
Market ClosedLast close Sep 8
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Janux Therapeutics, Inc. in the Healthcare sector is trading at $20.04 with a market capitalization of $829M. Wall Street consensus targets $36.24 (17 analysts), implying a +80.8% move over the next 12 months. The stock is currently 43% below its 52-week high of $35.34, remaining 29.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +80.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.73M | $0↓ | $10.00M | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$34.21M↑ | -$42.40M↓ | -$35.25M↑ | -$45.12M↓ | -$34.90M |
| Net Income | -$24.36M↑ | -$31.95M↓ | -$24.31M↑ | -$33.86M↓ | -$23.51M |
Peer Comparison
JNJUNHPFE
Fundamentals
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technolo...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$828.78M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-12.16%
Volume
Today's trading volume
1.06M
Recent News
Chipotle downgraded, Darden upgraded: Wall Street's top analyst calls
Chipotle downgraded, Darden upgraded: Wall Street's top analyst calls
Here Are Monday’s Top Wall Street Analyst Research Calls: AstraZeneca, Celestica, Chipotle Mexican Grill, Domino’s Pizza, Fortune Brands, Golar LNG, Jersey Mike’s Subs, Roku, and More
Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh initiations spanning pharma giants, fast-casual chains, and streaming players. Find out which names got bullish bets and which lost their analyst backing.
Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile
In the past, Janux Therapeutics, Inc. reported second-quarter 2026 results showing a net loss of US$21.97 million, or US$0.35 per share, compared with a net loss of US$33.86 million, or US$0.55 per share, a year earlier. For the first half of 2026, the company also reduced its net loss to US$46.33 million, or US$0.74 per share, signaling improving cost control and operating efficiency versus the prior-year period. We will now examine how Janux Therapeutics' reduced net loss and improving...
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates
Janux Therapeutics (JANX) delivered earnings and revenue surprises of -34.62% and -72.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership
Most small-cap biotech stocks are pure clinical bets. These three already have revenue on the books and insiders backing them with their own capital.